CDKN1A and urinary bladder cancer: Treatment of bladder cancer 5637 cells with ERIANIN resulted in a decrease in the number of cells in the G1 phase and an increase in those in the S and G2 phases; treatment also upregulated p21 protein expression and decreased p-AKT and AKT protein expression, indicating that ERIANIN inhibited bladder cancer cell proliferation through the PI3K/Akt pathway and blocked the cells in the G1 phase (90).